BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35127707)

  • 1. Identification of Tumor Antigens and Design of mRNA Vaccine for Colorectal Cancer Based on the Immune Subtype.
    Liu C; Papukashvili D; Dong Y; Wang X; Hu X; Yang N; Cai J; Xie F; Rcheulishvili N; Wang PG
    Front Cell Dev Biol; 2021; 9():783527. PubMed ID: 35127707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
    Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
    J Big Data; 2022; 9(1):92. PubMed ID: 35855914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
    Huang X; Zhang G; Tang T; Liang T
    Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
    You W; Ouyang J; Cai Z; Chen Y; Wu X
    Front Immunol; 2022; 13():827506. PubMed ID: 35874675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma.
    Zhang S; Li S; Wei Y; Xiong Y; Liu Q; Hu Z; Zeng Z; Tang F; Ouyang Y
    Front Cell Dev Biol; 2022; 10():879278. PubMed ID: 35846349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
    Hu J; Mo Z
    Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
    Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
    Front Genet; 2022; 13():853113. PubMed ID: 35734437
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development.
    Lu TL; Li CL; Gong YQ; Hou FT; Chen CW
    World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma.
    Wei S; Sun Q; Chen J; Li X; Hu Z
    Front Genet; 2022; 13():1068112. PubMed ID: 36579327
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
    Wang F
    Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Tumor Antigens and Immune Subtypes for the Development of mRNA Vaccines and Individualized Immunotherapy in Soft Tissue Sarcoma.
    Wu C; Duan Y; Gong S; Osterhoff G; Kallendrusch S; Schopow N
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically 'Cold' KIRC Tumours.
    Zhang S; Xia K; Chang Y; Wei Y; Xiong Y; Tang F; Peng J; Ouyang Y
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Five Tumor Antigens for Development and Two Immune Subtypes for Personalized Medicine of mRNA Vaccines in Papillary Renal Cell Carcinoma.
    Hu J; Yuan Z; Jiang Y; Mo Z
    J Pers Med; 2023 Feb; 13(2):. PubMed ID: 36836593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development.
    Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
    Front Genet; 2021; 12():701065. PubMed ID: 34527020
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development.
    Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
    J Transl Med; 2021 Aug; 19(1):352. PubMed ID: 34404444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines.
    Wang Y; Tan H; Yu T; Chen X; Jing F; Shi H
    Front Immunol; 2021; 12():755401. PubMed ID: 34917077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.